Lonza Group AG
LONN
Clasificación en acciones
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Precio por acción
$766.95
Capitalización bursátil
$53.57B
Cambio (1 día)
1.35%
Cambio (1 año)
9.01%
País
CH
Comercio Lonza Group AG (LONN)
Categoría
Healthcare
Ganancias de Lonza Group AG (LONN)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Lonza Group AG, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Lonza Group AG desde 2004 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2025 | $1.39B | 77.01% |
| 2024 | $783.78M | -16.56% |
| 2023 | $939.36M | -40.02% |
| 2022 | $1.57B | 87.88% |
| 2021 | $833.60M | -4.61% |
| 2020 | $873.87M | 18.24% |
| 2019 | $739.09M | -9.57% |
| 2018 | $817.28M | 49.73% |
| 2017 | $545.84M | 48.94% |
| 2016 | $366.48M | 7.42% |
| 2015 | $341.15M | 21.46% |
| 2014 | $280.87M | 138.68% |
| 2013 | $117.67M | -48.71% |
| 2012 | $229.45M | 23.16% |
| 2011 | $186.30M | -47.24% |
| 2010 | $353.12M | 96.17% |
| 2009 | $180.00M | -59.52% |
| 2008 | $444.71M | 39.23% |
| 2007 | $319.41M | 55.15% |
| 2006 | $205.88M | 36.16% |
| 2005 | $151.21M | -3.96% |
| 2004 | $157.45M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
